by CytoPrevent | Dec 26, 2021 | What’s new on CytoPrevent
Background The toxic effects of antineoplastic drugs used for cancer treatment have been well known since their introduction in the 1940s. However, beyond the patient safety concerns arising from the necessary therapeutic use of these drugs, the occupational risks to...
by CytoPrevent | Dec 22, 2021 | What’s new on CytoPrevent
Official Press Release from the Council Presidency and the European Parliament The Council presidency and the European Parliament have reached a provisional deal to update the carcinogens and mutagens directive, an EU law to protect workers from risks related...
by CytoPrevent | Dec 11, 2021 | Guidelines & Regulations
Abstract: What is a CSTD? A CSTD or closed system drug transfer device mechanically prohibits the transfer of environmental contaminants into the system and the escape of hazardous drugs (HD’s) or vapor concentrations outside the system. Does USP 800 require the use...
by CytoPrevent | Oct 5, 2021 | Studies
Pesqué Raphaëlle, Peyrilles Elodie, Jourdan Nathalie, Albert Odile, Sessink Paul, Madelaine Isabelle, Levert Hélène Abstract Background: Occupational exposure to cytotoxic drugs can lead to significant health problems. This study was designed to evaluate...
by CytoPrevent | Jul 30, 2021 | Board’s Position Papers
Hazardous Drugs (HD) Task Force Leader For maximizing safety The handling of Hazardous medical drugs in a cancer treatment unit requires a specific approach in order to avoid unnecessary risks for the healthcare staff, and more particularly for the nurses. The...